Regeneron Pharmaceuticals, Inc.
REGN
$892.48
$9.281.05%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 3.95B | 3.99B | 4.30B | 4.18B | 4.34B |
| Total Depreciation and Amortization | 421.00M | 408.10M | 395.30M | 366.60M | 341.40M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 313.50M | 475.70M | 170.10M | 557.10M | 578.40M |
| Change in Net Operating Assets | -94.10M | 349.30M | -125.60M | -825.60M | -243.30M |
| Cash from Operations | 4.59B | 5.22B | 4.74B | 4.28B | 5.01B |
| Capital Expenditure | -718.60M | -619.40M | -585.90M | -626.50M | -590.10M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -54.90M | -51.10M | 0.00 | -230.30M | -230.30M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.41B | -4.31B | -3.70B | -1.46B | -2.96B |
| Cash from Investing | -3.19B | -4.98B | -4.29B | -2.32B | -3.78B |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.15B | 1.22B | 1.27B | 1.48B | 1.52B |
| Repurchase of Common Stock | -2.94B | -2.81B | -3.18B | -2.88B | -2.53B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -1.79B | -1.59B | -1.91B | -1.40B | -1.01B |
| Foreign Exchange rate Adjustments | -400.00K | -600.00K | -400.00K | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -381.60M | -1.34B | -1.46B | 569.60M | 221.30M |
